Pembrolizumab-induced Eosinophilic Gastrointestinal Disorders

Masakatsu Nakamura; Toshimi Otsuka; Motona Kumagai; Tomiyasu Arisawa

doi:10.2169/internalmedicine.7725-21

Pembrolizumab-induced Eosinophilic Gastrointestinal Disorders

Masakatsu Nakamura
, Toshimi Otsuka
, Motona Kumagai
, Tomiyasu Arisawa

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

本文言語	英語
ページ（範囲）	267-269
ページ数	3
ジャーナル	Internal Medicine
巻	61
号	2
DOI	https://doi.org/10.2169/internalmedicine.7725-21
出版ステータス	出版済み - 2022
外部発表	はい

All Science Journal Classification (ASJC) codes

内科学

文献へのアクセス

10.2169/internalmedicine.7725-21

他のファイルとリンク

引用スタイル

@article{18149568de0c4e1ea8f07060a551f1ae,

title = "Pembrolizumab-induced Eosinophilic Gastrointestinal Disorders",

keywords = "Immune checkpoint inhibitor-related eosinophilic gastrointestinal disorders, Immune-related adverse event, Non-small cell lung cancer, Pembrolizumab, Secondary hypereosinophilic syndrome",

author = "Masakatsu Nakamura and Toshimi Otsuka and Motona Kumagai and Tomiyasu Arisawa",

year = "2022",

doi = "10.2169/internalmedicine.7725-21",

language = "English",

volume = "61",

pages = "267--269",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "2",

}

TY - JOUR

T1 - Pembrolizumab-induced Eosinophilic Gastrointestinal Disorders

AU - Nakamura, Masakatsu

AU - Otsuka, Toshimi

AU - Kumagai, Motona

AU - Arisawa, Tomiyasu

PY - 2022

Y1 - 2022

KW - Immune checkpoint inhibitor-related eosinophilic gastrointestinal disorders

KW - Immune-related adverse event

KW - Non-small cell lung cancer

KW - Pembrolizumab

KW - Secondary hypereosinophilic syndrome

UR - https://www.scopus.com/pages/publications/85122958395

UR - https://www.scopus.com/pages/publications/85122958395#tab=citedBy

U2 - 10.2169/internalmedicine.7725-21

DO - 10.2169/internalmedicine.7725-21

M3 - Article

C2 - 34248122

AN - SCOPUS:85122958395

SN - 0918-2918

VL - 61

SP - 267

EP - 269

JO - Internal Medicine

JF - Internal Medicine

IS - 2

ER -